NEW ORLEANS – ‍A once-daily oral medication, enlicitide, developed by Merck, significantly lowered LDL cholesterol levels in patients already taking statins⁢ and at high risk⁢ for cardiovascular events, according to Phase 3 trial results presented at ⁢the American Heart⁤ Association (AHA) Scientific Sessions on November 18, 2023. The trial, involving 2,900 participants, showed LDL cholesterol reductions of ⁢up to 60%, with ⁣two-thirds of patients experiencing at least a 50% decrease. STAT News reported the findings from the conference.

This achievement marks ⁤a key milestone for Merck, bringing them closer to developing an oral medication that matches the⁢ cholesterol-lowering efficacy of injectable PCSK9 inhibitors, a⁤ class of drugs currently administered via injection. The‍ success of enlicitide could ⁢offer a ⁢more ‍convenient treatment option‍ for millions at risk of heart attack‍ and stroke.

Understanding⁢ Enlicitide and PCSK9 Inhibition

Enlicitide is an oral PCSK9 ⁤inhibitor. The‍ American Heart Association explains that PCSK9 (proprotein convertase subtilisin/kexin type 9) is a protein that ⁢prevents the‍ liver from removing LDL cholesterol from the blood. Inhibiting PCSK9 allows the liver to clear more LDL ⁣cholesterol, reducing levels in the bloodstream. Currently ⁣available⁣ PCSK9⁤ inhibitors, such⁢ as evolocumab and alirocumab,‍ are administered via injection.

High LDL cholesterol is a major risk⁤ factor⁢ for atherosclerotic cardiovascular disease (ASCVD),which includes heart attack,stroke,and peripheral artery disease. Statins are the first-line treatment for lowering LDL cholesterol, but many patients cannot tolerate high doses due to side⁣ effects or do not ⁤achieve sufficient reductions with statins alone. This is ⁢where additional therapies like PCSK9 inhibitors become crucial.

Phase 3⁢ Trial Details and Results

The Phase 3 clinical trial, known as the CLEAR-ASCVD trial, enrolled 2,900 individuals with elevated LDL cholesterol despite‍ being on ⁢maximally tolerated statin therapy. Participants also had a history of,or were at high risk for,major cardiovascular events ‍due ⁣to⁣ factors like obesity,diabetes,or coronary heart disease. The trial was a ‍randomized, ⁢double-blind, placebo-controlled study.

Key findings from the⁢ trial include:

• LDL Cholesterol Reduction: Enlicitide demonstrated up to a 60% reduction in LDL cholesterol ⁢levels compared⁢ to placebo.
• Significant‍ Response ‍Rate: Approximately two-thirds of⁢ patients treated with enlicitide achieved at least a ⁢50% reduction⁤ in LDL cholesterol.
• Safety Profile: The drug ‍appeared to have a manageable safety⁤ profile,with adverse events similar to ⁢those observed with placebo. detailed safety data is still being analyzed.

Merck⁣ plans to submit the data ‍to regulatory authorities, including the U.S. Food and drug Administration (FDA), for potential approval. The ⁢timeline⁣ for approval ⁢remains uncertain.

impact ⁤and Future Implications

The potential⁤ approval of enlicitide would represent a significant advancement in⁣ cardiovascular disease prevention. ⁤An oral PCSK9 inhibitor offers ⁢a more ⁢convenient alternative to injections, possibly⁣ improving patient adherence and expanding access to⁤ this important class of medications.

The success of enlicitide could also spur further research into oral⁣ PCSK9 inhibitors, potentially⁣ leading to even ⁤more ⁤effective and convenient treatments for high cholesterol. The current injectable PCSK9 inhibitors have demonstrated ample benefits in reducing‍ cardiovascular ‍events,and an oral option could broaden their reach.